TruDi probe spotlights Johnson & Johnson (JNJ) surgical AI safety risks

TruDi scrutiny spotlights J&J's surgical AI risks

A Reuters investigation finds that artificial intelligence is spreading rapidly through modern healthcare but unevenly, with safety records and regulatory struggles drawing fresh scrutiny for Johnson & Johnson. The probe highlights Acclarent, a J&J subsidiary, which adds machine‑learning software to its TruDi Navigation System in 2021 and calls the update “a leap forward” to help ear, nose and throat surgeons guide instruments during sinus procedures. Federal regulators receive more than 100 reports of technical failures or patient injuries after the update, and at least 10 patients are reported harmed between late 2021 and 2025, with incidents ranging from leaking spinal fluid and punctured skull bases to strokes caused by damaged arteries.

Several patients file lawsuits alleging the TruDi system gives incorrect location information that misleads surgeons, naming cases such as Erin Ralph, who suffers a stroke after a 2022 surgery, and Donna Fernihough, who experiences a similar injury in 2023. Acclarent and device distributors reject a causal link, saying there is “no credible evidence” tying the machine‑learning features to injuries. Court records show disputes over surgeon ties to Acclarent and allegations the company rushed the product to market and accepted “only 80% accuracy” for some features.

The reporting also places the Acclarent experience in a wider pattern of regulatory and post‑market challenges for AI in devices. By 2025 the FDA authorizes more than 1,300 medical devices that use artificial intelligence—roughly twice as many as a few years earlier—and a review finds many such products are later recalled, often within a year of approval. The recall rate for AI‑based devices is about double that of similar technologies without machine learning, and federal safety databases contain hundreds of reports involving AI products, from prenatal ultrasound software that allegedly mislabels fetal structures to heart monitors that allegedly fail to detect abnormal rhythms. Manufacturers maintain most incidents do not lead to patient harm, but the reporting underscores regulatory and safety obstacles for companies advancing AI‑enabled devices.

Serotonergic drugs reshape CNS pipeline

Separately, Johnson & Johnson is cited among major drugmakers active in a trend toward novel serotonergic agonists (NSAs), a next‑generation class of central nervous system therapies that aim to deliver faster onset and greater efficacy than conventional SSRIs for depression, PTSD, anxiety and addiction. The global depression and anxiety treatment market is estimated at $50–60 billion annually, and the broader neuropsychiatric market is projected to exceed $150 billion by the decade’s end, prompting large pharmaceutical companies to watch clinical inflection points and potential commercialization pathways closely.

Smaller biotechs also move quickly: Helus Pharma appoints Michael Cola as CEO to guide late‑stage development and commercialization and advances HLP004 and HLP003 toward Phase 2 and Phase 3 readouts this year. The industry views successful NSA platforms as scalable across indications, creating strategic partnership and acquisition options for firms such as Johnson & Johnson seeking to refresh CNS pipelines.